"Fusen Pharm(01652) has successfully developed the "Piracetam Injection" and obtained approval for its market launch."

FUSEN PHARM (01652) announced that the market application of the "Piracetam Injection" developed by its wholly-owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Co., Ltd. has been approved by the China National Medical Products Administration. It is approved for use in memory decline and mild to moderate cognitive impairment caused by various reasons such as acute and chronic cerebrovascular diseases, traumatic brain injury, various toxic brain diseases, and can also be used for children with delayed intellectual development. "Piracetam Injection" is a brain metabolism-improving drug and the first drug developed based on the structure of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). It can activate adenylate kinase, increase the ATP/ADP ratio of the brain, and enhance the absorption and utilization of amino acids, proteins, and glucose by the brain. It promotes brain cell metabolism and improves the brain cortex's resistance to hypoxia. In addition, in vitro experiments have shown that Piracetam can protect mitochondria from oxidative stress and have a protective effect on them. As a brain metabolism-improving drug, Piracetam has been widely used in clinical practice due to its significant effects and minimal side effects. It is recommended for the treatment of Alzheimer's disease in the "Chinese Guidelines for Dementia and Cognitive Impairment Diagnosis and Treatment" and the "Chinese Guidelines for Diagnosis and Treatment Process of Cognitive Impairment in the Elderly"; and its neuroprotective effects have been included in the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke" and recommended in the "Expert Consensus on Clinical Management of Aphasia after Stroke". This product is a national medical insurance category B variety. According to data from MI Healthcare Network, sales of Piracetam Injection in the three largest end markets in China are expected to exceed 250 million RMB by 2025. The 20ml:8mg specification of Piracetam Injection developed by the group has been sold in the domestic market for many years and has a high market acceptance. The specifications approved during the same period include 5ml:1mg and 15ml:3mg, which can meet the treatment needs of different patients at the same time. "Piracetam Injection" is another important product of the group, further enriching the group's product pipeline in the field of the nervous system. The launch of this product will provide more treatment options for patients with cerebrovascular diseases and cognitive impairment.